Founded in 2019, Artiria Medical is on a mission to revolutionize minimally invasive surgical interventions for the better treatment of stroke patients. Its leading product is a novel real-time deflectable guidewire that enables neurointerventional surgeons to access the diseased site faster. The product has already been used in humans and treated its first patients in the third quarter of 2023 while gaining significant traction from physicians in the neurointerventional setting.
The EPFL-spinoff has finalised its series A2 round led by 4FOX Ventures, was joined by the Wyss Center for Bio and Neuroengineering, and existing investors, including Verve Ventures, the Zürcher Kantonalbank, NEST pension fund, and business angels. In addition the company obtained a Tech Growth Loan from the Foundation for technological innovation (FIT).
“This funding round shall enable Artiria to study the unique features of our product with key opinion leaders in Europe and the US through a randomized controlled study against the market-leading products,” said Guillaume Petit-Pierre, CEO and co-founder of Artiria. “Following the already secured FDA clearance, this study will further enable Artiria to apply for European market approval, thus significantly extending the scope of the company.”
“We believe that Artiria’s innovative solution will advance the treatment of stroke with a product enabling safe yet accelerated procedures, and we are delighted to be part of this great journey,” said Valentin Chenaux, General Partner of 4FOX Ventures.
(Press release/RAN)
Please login or sign up to comment.
Commenting guidelines